|
Compounds to Treat Obesity (104-010)
Obesity is now considered as a global epidemic with over one billion people being overweight. About $33 billion is being spent each year in USA on weight reduction products. To date no satisfactory drug is available to control obesity. Therefore, millions of dollars are spent each year towards the development of new treatments to fight this epidemic.
Neuropeptide...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): Ambikaipakan Balasubramanium
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics > Biomaterials, Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Diseases & Disorders, Technology Classifications > Life Sciences > Diseases & Disorders > Cardiovascular, Technology Classifications > Life Sciences > Diseases & Disorders > Diabetes-related
|
|
Immunotherapeutic Phospholipid for Cancer Treatment (2023-012)
A hallmark feature of malignant cell growth is the presence of an immunosuppressive tumor microenvironment (TME). Cancer cells have evolved mechanisms that promote the escape from the host immune attack which sustains tumor growth. Reversal of immunosuppression in the TME is now considered a powerful approach for cancer treatment.
The TME is a complex...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): Xiaoyang Qi
Keywords(s): Cancer, Healthcare, Immune System, Immunotherapeutic Phospholipid, Tumor Microenvironment (TME)
Category(s): Technology Classifications > Life Sciences > Diseases & Disorders > Cancer, Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Diseases & Disorders, Technology Classifications > Life Sciences > Diseases & Disorders > Autoimmune, Technology Classifications > Life Sciences > Therapeutics > Biomaterials, Technology Classifications > Life Sciences > Therapeutics
|
|
Rapid 3d-Bioprinting of Vascular Tissue Models for Drug Discovery (2022-081)
Preclinical drug studies typically rely on animal experimentation. However, due to the decreasing drug attrition rate, new cell culture models, known as microphysiological systems (MPSs) or organs-on-chips (OOCs), have been developed for preliminary drug testing.
MPSs allow for the recreation of human tissue-tissue interfaces, and consist of a base...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): Riccardo Barrile
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics > Biomaterials, Technology Classifications > Life Sciences > Biomedical, Technology Classifications > Life Sciences > Therapeutics > Small Molecule, Technology Classifications > Life Sciences
|
|
Patient-specific biodegradable drug delivery (2022-035)
Biomaterial implants fabricated from synthetic polymers have been extensively used in regenerative medicine applications and are regularly formulated into erodible drug delivery systems or degradable scaffolds. These implants are most commonly degraded by hydrolysis. While these materials can be effective, their degradation rates are pre-determined;...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): Karina Bruce, Dylan Marques, Alan Fullenkamp, John Martin
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics > Biomaterials, Technology Classifications > Life Sciences > Regenerative Medicine, Technology Classifications > Life Sciences > Biomedical, Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Therapeutics
|
|
New method for treating autoimmune diseases
Subtitle
Image*
[UPLOAD IMAGE HERE]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830342/bin/nihms770695f2.jpg
Description*
Dr. Laura Conforti has discovered a way that uses lipid-derived nanovesicles functionalized with antibodies against membrane proteins expressed only on the surfaces of the subset of immune cells involved in the pathology...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): Yeoheung Yun, Laura Conforti
Keywords(s): Autoimmune Diseases Treatment, Healthcare, Kv1.3 Ion Channel Targeting, Lipid-Derived Nanovesicles, RNAi Drug Delivery
Category(s): Technology Classifications > Life Sciences > Biomedical, Technology Classifications > Life Sciences > Diseases & Disorders > Autoimmune, Technology Classifications > Life Sciences > Therapeutics > Biomaterials, Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Diseases & Disorders
|